CN117003720A - 化合物芙蓉花素及其制备方法和用途 - Google Patents
化合物芙蓉花素及其制备方法和用途 Download PDFInfo
- Publication number
- CN117003720A CN117003720A CN202210467131.5A CN202210467131A CN117003720A CN 117003720 A CN117003720 A CN 117003720A CN 202210467131 A CN202210467131 A CN 202210467131A CN 117003720 A CN117003720 A CN 117003720A
- Authority
- CN
- China
- Prior art keywords
- compound
- ethyl acetate
- ethanol
- water
- petroleum ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 235000005206 Hibiscus Nutrition 0.000 title abstract description 14
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 title abstract description 14
- 241001075721 Hibiscus trionum Species 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 244000048199 Hibiscus mutabilis Species 0.000 claims description 33
- 239000003208 petroleum Substances 0.000 claims description 29
- 238000000605 extraction Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 235000003973 Hibiscus mutabilis Nutrition 0.000 claims description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 21
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 21
- 239000012071 phase Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 13
- 239000000469 ethanolic extract Substances 0.000 claims description 12
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000287 crude extract Substances 0.000 claims description 11
- 238000010828 elution Methods 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 9
- 239000007791 liquid phase Substances 0.000 claims description 7
- 238000010898 silica gel chromatography Methods 0.000 claims description 7
- 241000628997 Flos Species 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 125000001033 ether group Chemical group 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 5
- 239000012498 ultrapure water Substances 0.000 claims description 5
- 239000000273 veterinary drug Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 claims 1
- 241000218033 Hibiscus Species 0.000 abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- -1 1 '-methoxy-3,5,7,4', 3', 4' -hexahydroxyflavone Chemical compound 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 26
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 22
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 12
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 11
- 235000008777 kaempferol Nutrition 0.000 description 11
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 4
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 208000007106 menorrhagia Diseases 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- GPGOCTLAUAHUQO-UHFFFAOYSA-N 3-hydroxy-2-(4-hydroxyphenyl)chromen-4-one Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=CC=CC=C2O1 GPGOCTLAUAHUQO-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 240000004153 Hibiscus sabdariffa Species 0.000 description 2
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010013642 Drooling Diseases 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/40—Separation, e.g. from natural material; Purification
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药、保健品领域,具体涉及一种新的化合物芙蓉花素及其制备方法和用途。本发明化合物是首次从木芙蓉花中提取分离得到,结构如式Ⅰ,化学式为C23H18O8,化学命名为1”‑甲氧基‑3,5,7,4',3”',4”'‑六羟基黄酮,并命名为芙蓉花素,英文名Mutabilfloin。本发明化合物具有抗炎等多用途应用前景。
Description
技术领域
本发明属于医药、保健品领域,具体涉及一种新的化合物芙蓉花素及其制备方法和用途。
背景技术
木芙蓉Hibiscus mutabilis.L为锦葵科木槿属植物,其花、叶均可以入药。药用价值记载始于宋代的《本草图经》,“地芙蓉,生鼎州。味辛,平,无毒。花主恶疮,叶以敷贴肿痛,九月采”。木芙蓉又名桦木、拒霜、下排杯(壮语)、奔娘咋(苗名),在四川、浙江、福建、云南、台湾等多地均有种植,海外种植资源多分布在韩国、日本、尼泊尔、老挝、泰国等多地。经过十多年的研究,成都市植物园成功研究培育出18个木芙蓉品种。木芙蓉叶收载于2020版《中国药典》,其花收载于2019版《广东省中药材标准第三册》。味辛,性平,具有解毒消肿,清热凉血排脓之功效,外用可治疗痈疽疔疮发背、烧烫伤、乳腺炎、跌打损伤等,内服用于治疗肺热咳嗽,月经、白带过多等。《本草纲目》记载:“木芙蓉花并叶,气平而不寒不热,味微辛而性滑涎粘,其治痈肿之功,殊有神效”。现代药理研究表明其不仅具有抗炎镇痛、抗氧化、抗过敏、降低血糖等作用,还被广泛应用于化妆品和食品的原料或添加品等方面。
木芙蓉在要药用价值方面,具有清热解毒,消肿排脓,凉血止血的功效。用于肺热咳嗽,月经过多,白带;外用治痈肿疮疖,乳腺炎,***炎,腮腺炎,烧烫伤,毒蛇咬伤,跌打损伤。用法用量:0.3~1两;外用适量,以鲜叶、花捣烂敷患处或干叶、花研末用油、凡士林、酒、醋或浓茶调敷。已报道经方验方有:1、治吐血、子宫出血、火眼、疮肿、肺痈:芙蓉花三钱至一两,煎服。(《上海常用中草药》);2、治痈疽肿毒:木芙蓉花、叶,丹皮。煎水洗。(《湖南药物志》);3、治蛇头疔、天蛇毒:.鲜木芙蓉花二两,冬蜜五钱。捣烂敷,日换二至三次。(福建《民间实用草药》);4、治水烫伤:木芙蓉花晒干,研末,麻油调搽。(《湖南药物志》);5、治灸疮不愈:芙蓉花研末敷。(《奇效良方》);6、治虚痨咳嗽:芙蓉花二至四两,鹿衔草一两,黄糖二两,炖猪心肺服;无糖时加盐亦可。(《重庆草药》);7、治经血不止:拒霜花、莲蓬壳等分。为末,每用米次下二钱。(《妇人良方》)。
木芙蓉中化学成分主要是黄酮类及其苷类、有机酸类以及挥发性成分等,其中黄酮类及其苷类成分为木芙蓉的特征性成分和有效成分,迄今为止已从木芙蓉中分离鉴定出73个黄酮类化合物,包括从木芙蓉叶中分离鉴定出的48个黄酮类成分和从木芙蓉花分离鉴别出的36个黄酮类成分,主要是以山奈酚、槲皮素、芹菜素等为母核的黄酮苷类化合物。在此应用背景下,本发明的发明人在对木芙蓉花的研究中,发现了一种新的化合物。
发明内容
本发明所解决的第一个技术问题提供一种新的化合物,结构如式Ⅰ,化学式为C23H18O8。
本发明式Ⅰ化合物的化学命名为1″-甲氧基-3,5,7,4',3″′,4″′-六羟基黄酮,并命名为芙蓉花素,英文名Mutabilfloin。本发明式Ⅰ化合物的核磁数据(600MHz,CD3OH,JinHz)见表1。
表1
a)测量频率为600MHz;b)测量频率为150MHz。
本发明式Ⅰ所述化合物的理化性质为:棕褐色粉末,易溶于甲醇。
本发明式Ⅰ所述化合物的波谱数据:(c=0.05,MeOH),IR(KBr)vmax 3458,1733,1682,1560;UVλmax 205nm;LC-MS:m/z423.16;1H NMR(600MHz,Methanol-d4)δ7.62(2H,d,J=8.2Hz,H-2',6'),6.78(2H,d,J=8.1Hz,H-3',5'),6.75(1H,d,J=2.1Hz,H-2″′),6.70(1H,d,J=8.3Hz,H-5″′),6.65(1H,dd,J=8.4,2.2Hz,H-6″′),6.29(1H,s,H-6),4.81(1H,q,J=7.2Hz,H-1″),1.66(3H,d,J=7.2Hz,2″-CH3);13C NMR(151MHz,MeOD)δ160.4(C-2),123.8(C-3),177.7(C-4),160.3(C-5),98.9(C-6),163.0(C-7),112.5(C-8),155.7(C-9),105.1(C-10),136.8(C-1'),131.1(C-2'),116.1(C-3'),148.6(C-4'),116.1(C-5'),131.1(C-6'),33.0(C-1″),18.5(2″-CH3),138.2(C-1″′),115.4(C-2″′),144.0(C-3″′),146.0(C-4″′),116.0(C-5″′),119.1(C-6″′)。
本发明式Ⅰ所述化合物的旋光度(c 0.05,甲醇),从红外光谱中可以观察到3458cm-1、1733cm-1、1682cm-1、1560cm-1处有吸收,表明化合物中羟基、羰基以及苯环。紫外光谱显示该化合物在205nm、280nm处有较强吸收。LC-MS准分子离子峰在m/z423.16[M+H]+处出现(计算值为423.11),不饱和度Ω=15,确定分子式为C23H18O8。
本发明式Ⅰ所述化合物的1H NMR谱和1H-1HCOSY谱(见表1)显示δ7.62(2H,J=8.2Hz,H-2',6')、δ6.87(2H,J=8.1Hz,H-3',5')为4'-羟基黄酮醇的特征信号,且HSQC谱显示δH 7.62与δC131.1相连,δH 6.87与δC116.1相连。将化合物*24的13C数据与山奈酚的13C核磁共振数据进行比较,确定分子中的黄酮母核部分为山奈酚。通过1H NMR谱并结合耦合值推出δH6.75(1H,d,J=2.1Hz),6.70(1H,d,J=8.3Hz),6.65(1H,dd,J=8.4,2.2Hz)为苯环上ABX***氢信号。通过HSQC谱和HMBC谱显示δC160.3(C-5)和δC163.0(C-7)质子上连接羟基、δC105.9(C-4)为叔碳质子、δC98.9(C-6)为单峰(s),表明山奈酚母核部分C-8位被取代。1H NMR谱和1H-1HCOSY谱显示δH4.81处为亚甲基质子信号,有一个四重峰(q),J=7.2Hz,与三个质子耦合,δH1.66处为甲基质子信号,与两个质子耦合,故判断化合物*24中存在一个乙基。HMBC谱显示叔碳δC 33.0与δC 18.5,112.5,115.4,119.1,138.2相关,故可以确定ABX***苯环、乙基与山奈酚母核结构位置,且由不饱和度Ω=15判断可知,山奈酚母核部分与苯基取代基部分之间不存在环状结构。综上所述,确定本发明式Ⅰ化合物的结构为1″-甲氧基-3,5,7,4',3″′,4″′-六羟基黄酮,即1″-methoxy-3,5,7,4',3″′,4″′-hexahydroxyflavone,并命名为芙蓉花素,英文名Mutabilfloin。
本发明所解决的第二个技术问题是提供该化合物的制备方法,本发明式Ⅰ化合物是通过提取方法制备而得,所采用的原料为干燥木芙蓉花,即开花期采摘初开放的花朵或待开放的花蕾,晒干或烘干即得。
本发明式Ⅰ化合物的制备方法包括如下步骤:
A、粉碎干燥木芙蓉花,用乙醇提取,收集滤液,除去乙醇,得到木芙蓉花乙醇提取物粗浸膏;
B、步骤A所得木芙蓉花乙醇提取物粗浸膏加水混悬,分别使用石油醚(60~90℃)、乙酸乙酯、正丁醇(水饱和)依次萃取3-5次,分别收集萃取液,除去萃取液,分别得到石油醚部位、乙酸乙酯部位、正丁醇部位,剩余为水相部位;
C、取乙酸乙酯部位经正相硅胶柱色谱分离,以石油醚-乙酸乙酯为洗脱***进行梯度洗脱,收集馏分用TLC进行检视合并,依次得到7个组分,命名为Fr.YA~Fr.YG,收集Fr.YC备用;
D、取步骤C所得Fr.YC用MCI中压柱进行分离,以甲醇-水溶剂***进行梯度洗脱,收集馏分用TLC进行检测合并,依次得到以下组分,分别命名为Fr.YC1~13,收集Fr.YC 6备用;
E、取步骤D所得Fr.YC 6,经半制备液相纯化,以体积分数62%甲醇溶液为流动相,得到本发明式Ⅰ化合物。
上述制备方法的技术方案中:
步骤A所述乙醇为体积分数70-100%乙醇;优选,体积分数90%乙醇。
步骤A所述提取方法为回流提取。
步骤A所述提取方法中回流提取的提取条件为1-3次,每次0.5-3小时;优选的,提取条件为2次,每次2小时.
步骤A所述除去乙醇的方法采用减压回收,以无醇味为终点。
步骤B中木芙蓉花乙醇提取物粗浸膏加水量为8-12倍量;优选10倍量。
步骤B中所述水为超纯水。
步骤B依次采用等体积的石油醚(60~90℃)、乙酸乙酯、正丁醇(水饱和)萃取。
步骤B依次采用石油醚(60~90℃)、乙酸乙酯、正丁醇(水饱和)萃取的次数为1-5次,优选采用萃取次数为3次。
步骤C石油醚-乙酸乙酯溶剂***为按照20:1,8:1,5:1,2:1,1:1,1:2,1:4,1:10,0:100梯度进行洗脱,收集。
步骤D甲醇-水溶剂洗脱***依次为50:50,60:40,70:30,80:20,90:10,100:0,收集馏分用TLC进行检测合并,依次得到以下组分,分别命名为Fr.YC1~13。
如步骤C取乙酸乙酯部位80g经正相硅胶柱色谱分离,以石油醚-乙酸乙酯为洗脱***按照20:1,8:1,5:1,2:1,1:1,1:2,1:4,1:10,0:100梯度进行洗脱,收集,共接馏分127瓶。然后收集的127瓶馏分经TLC进行检视合并,得到7个组分,命名为Fr.YA~Fr.YG,其中,1-15为Fr.YA,26-37为Fr.YB,38-52为Fr.YC,53-68为Fr.YD,69-90为Fr.YE,91-109为Fr.YF,110-127为Fr.YG。收集Fr.YC备用;
步骤C所得Fr.YC对应为石油醚:乙酸乙酯=2:1洗脱的部分。
步骤D按取乙酸乙酯部位80g计算,甲醇-水溶剂洗脱***依次为50:50,60:40,70:30,80:20,90:10,100:0,共接馏分90瓶。用TLC进行检测合并,依次得到以下组分,分别命名为Fr.YC1~13,其中:1-4为Fr.YC 1,5-9为Fr.YC 2,10-13为Fr.YC 3,14-19为Fr.YC 4,20-24为Fr.YC 5,25-28为Fr.YC 6,29-33为Fr.YC 7,34-38为Fr.YC 8,39-44为Fr.YC 9,45-48为Fr.YC 10,49-62为Fr.YC 11,63-79为Fr.YC 12,80-90为Fr.YC 13。
步骤D所得Fr.YC 6对应为甲醇-水溶剂***=60:40洗脱的部分,即60%甲醇。
步骤E经半制备液相纯化,以体积分数62%甲醇溶液为流动相,出峰时间33min。
最优选的,本发明式Ⅰ化合物的制备方法如下:
A、将干燥木芙蓉花粉碎成粗粉,用体积分数90%乙醇回流提取2次,每次2h,滤过后合并滤液,减压回收至无醇味,得到木芙蓉花乙醇提取物粗浸膏;
B、加入10倍量超纯水混悬提取物,分别使用等体积石油醚(60~90℃)、乙酸乙酯、正丁醇(水饱和)依次萃取3次,合并各萃取液,减压回收,得到石油醚部分、乙酸乙酯部分、正丁醇部分,剩余为水相部位;
C、取乙酸乙酯部位经正相硅胶柱色谱分离,以石油醚-乙酸乙酯为洗脱***进行梯度洗脱,收集馏分用TLC进行检视合并,依次得到7个组分,命名为Fr.YA~Fr.YG,收集Fr.YC备用;
D、取步骤C所得Fr.YC用MCI中压柱进行分离,以甲醇-水溶剂***进行梯度洗脱,收集馏分用TLC进行检测合并,依次得到以下组分,分别命名为Fr.YC1~13,收集Fr.YC 6备用;
E、去步骤D所得Fr.YC 6,经半制备液相纯化,以体积分数62%甲醇溶液为流动相,出峰时间33min,得到本发明式Ⅰ化合物。
采用上述制备方法,以20kg干燥木芙蓉花投料为例,步骤A可以得到3.34kg木芙蓉花乙醇提取物粗浸膏;步骤B可以得到93.6g石油醚部分,89.7g乙酸乙酯部分,389g正丁醇部分,剩余为水相部位;步骤C取乙酸乙酯部位80g,以石油醚-乙酸乙酯为洗脱***按照20:1,8:1,5:1,2:1,1:1,1:2,1:4,1:10,0:100梯度进行洗脱,收集,共接馏分127瓶。然后收集的127瓶馏分经TLC进行检视合并,得到7个组分,命名为Fr.YA~Fr.YG,其中,1-15为Fr.YA,26-37为Fr.YB,38-52为Fr.YC,53-68为Fr.YD,69-90为Fr.YE,91-109为Fr.YF,110-127为Fr.YG。收集Fr.YC备用;收集得到馏分Fr.YC 14.97g;然后Fr.YC用MCI中压柱进行分离,经过甲醇-水溶剂***(50:50,60:40,70:30,80:20,90:10,100:0)洗脱,共接馏分90瓶。1-4为Fr.YC 1,5-9为Fr.YC 2,10-13为Fr.YC 3,14-19为Fr.YC 4,20-24为Fr.YC 5,25-28为Fr.YC 6,29-33为Fr.YC 7,34-38为Fr.YC 8,39-44为Fr.YC 9,45-48为Fr.YC 10,49-62为Fr.YC 11,63-79为Fr.YC 12,80-90为Fr.YC 13。收集的Fr.YC 6对应为甲醇-水溶剂***=60:40洗脱的部分,即60%甲醇,经半制备液相纯化得到本发明式Ⅰ化合物。
本发明解决的第三个技术问题是提供式Ⅰ化合物的至少一种新用途。
通过药理试验证明,本发明式Ⅰ化合物还具有在制备抗炎的药物、保健品、化妆品中的新用途。
本发明解决的第四个技术问题是提供式Ⅰ化合物为原料制备的衍生产品。
以本发明式Ⅰ化合物为原料,加入药学上可接受的辅助性成分制备而得的药物。
以本发明式Ⅰ化合物为原料,加入保健品可接受的辅助性成分制备而得的保健品。
以本发明式Ⅰ化合物为原料,加入化妆品可接受的辅助性成分制备而得的化妆品。
以本发明式Ⅰ化合物为原料,加入兽药可接受的辅助性成分制备而得的兽药。
本发明的有益效果:本发明通过提取分离技术获得了一种全新的式Ⅰ化合物,并确认了其具有抗炎的医药用途,为公众提供了一种全新的化合物及其制备方法和多种应用前景。
附图说明
图1提取分离与纯化流程图。
图2本发明式Ⅰ化合物对RAW264.7细胞增殖的影响。
图3本发明式Ⅰ化合物对TNF-α释放量的影响。
注:与空白组比较##P<0.01;与模型组比较*P<0.05,**P<0.01,****P<0.001
图4本发明式Ⅰ化合物对NO释放量的影响。
注:与空白组比较##P<0.01;与模型组比较**P<0.01,***P<0.001
具体实施方式
以下通过对本发明具体实施方式的描述说明但不限制本发明。
本发明化合物,结构如式Ⅰ,化学式为C23H18O8。
本发明化合物的化学命名为1″-甲氧基-3,5,7,4',3″′,4″′-六羟基黄酮,并命名为芙蓉花素,英文名Mutabilfloin。
本发明式Ⅰ化合物是首次被发现,发明人通过从木芙蓉花的乙醇提取物进行化学成分分离纯化得到的单体化合物。
本发明中木芙蓉花样品于2019年10月中旬采集于四川省成都市三合镇木芙蓉花种植基地,自然阴干,经鉴定为木芙蓉Hibiscus mutabilis L.的干燥花。
一、本发明式Ⅰ化合物的提取分离与纯化
1提取分离与纯化
1.1提取
将干燥木芙蓉花20kg粉碎成粗粉,用体积分数90%乙醇回流提取2次,每次2h,滤过后合并滤液,减压回收至无醇味,得到木芙蓉花乙醇提取物粗浸膏(3.34kg)。加入10倍量超纯水混悬提取物,分别使用等体积石油醚(60~90℃)、乙酸乙酯、正丁醇(水饱和)依次萃取3次,合并各萃取液,减压回收,得到石油醚部分(93.6g)、乙酸乙酯部分(89.7g)、正丁醇部分(389.0g),剩余为水相部位。
1.2分离与纯化
取乙酸乙酯部位浸膏80.0g经正相硅胶柱色谱分离,以石油醚-乙酸乙酯为洗脱***进行梯度洗脱,收集馏分用TLC进行检视合并,得到7个组分,命名为Fr.YA~Fr.YG。Fr.YA(10.97g)、YC(14.97g)段分别用MCI中压柱进行分离,以甲醇-水溶剂***进行梯度洗脱,收集馏分用TLC进行检测合并,得到组分Fr.YA 1~11,Fr.YC1~13。其中,Fr.YC 6经半制备液相纯化,体积分数62%甲醇溶液为流动相,得到本发明式Ⅰ化合物。提取分离与纯化流程图如下图1所示。
通过提取纯化方法得到的本发明式Ⅰ化合物为棕褐色粉末,易溶于甲醇。旋光度(c 0.05,甲醇),从红外光谱中可以观察到3458cm-1、1733cm-1、1682cm-1、1560cm-1处有吸收,表明化合物中羟基、羰基以及苯环。紫外光谱显示该化合物在205nm、280nm处有较强吸收。LC-MS准分子离子峰在m/z423.16[M+H]+处出现(计算值为423.11),不饱和度Ω=15,确定分子式为C23H18O8。1H NMR谱和1H-1HCOSY谱(见表1)显示δ7.62(2H,J=8.2Hz,H-2',6')、δ6.87(2H,J=8.1Hz,H-3',5')为4'-羟基黄酮醇的特征信号,且HSQC谱显示δH7.62与δC131.1相连,δH 6.87与δC116.1相连。将化合物*24的13C数据与山奈酚的13C核磁共振数据进行比较,确定分子中的黄酮母核部分为山奈酚。通过1H NMR谱并结合耦合值推出δH6.75(1H,d,J=2.1Hz),6.70(1H,d,J=8.3Hz),6.65(1H,dd,J=8.4,2.2Hz)为苯环上ABX***氢信号。通过HSQC谱和HMBC谱显示δC160.3(C-5)和δC163.0(C-7)质子上连接羟基、δC105.9(C-4)为叔碳质子、δC98.9(C-6)为单峰(s),表明山奈酚母核部分C-8位被取代。1HNMR谱和1H-1HCOSY谱显示δH4.81处为亚甲基质子信号,有一个四重峰(q),J=7.2Hz,与三个质子耦合,δH1.66处为甲基质子信号,与两个质子耦合,故判断化合物*24中存在一个乙基。HMBC谱显示叔碳δC 33.0与δC 18.5,112.5,115.4,119.1,138.2相关,故可以确定ABX***苯环、乙基与山奈酚母核结构位置,且由不饱和度Ω=15判断可知,山奈酚母核部分与苯基取代基部分之间不存在环状结构。综上所述,确定本发明式Ⅰ化合物的结构为1″′甲氧基-3,5,7,4',3″,4″-六羟基黄酮,即1″′-methoxy-3,5,7,4',3″,4″-hexahydroxyflavone,并命名为芙蓉花素,英文名Mutabilfloin。
本发明式Ⅰ所述化合物的波谱数据:(c=0.05,MeOH),IR(KBr)vmax 3458,1733,1682,1560;UVλmax 205nm;LC-MS:m/z423.16;1H NMR(600MHz,Methanol-d4)δ7.62(2H,d,J=8.2Hz,H-2',6'),6.78(2H,d,J=8.1Hz,H-3',5'),6.75(1H,d,J=2.1Hz,H-2″′),6.70(1H,d,J=8.3Hz,H-5″′),6.65(1H,dd,J=8.4,2.2Hz,H-6″′),6.29(1H,s,H-6),4.81(1H,q,J=7.2Hz,H-1″),1.66(3H,d,J=7.2Hz,2″-CH3);13C NMR(151MHz,MeOD)δ160.4(C-2),123.8(C-3),177.7(C-4),160.3(C-5),98.9(C-6),163.0(C-7),112.5(C-8),155.7(C-9),105.1(C-10),136.8(C-1'),131.1(C-2'),116.1(C-3'),148.6(C-4'),116.1(C-5'),131.1(C-6'),33.0(C-1″),18.5(2″-CH3),138.2(C-1″′),115.4(C-2″′),144.0(C-3″′),146.0(C-4″′),116.0(C-5″′),119.1(C-6″′)。
二、本发明式Ⅰ化合物的用途
小鼠巨噬细胞株RAW264.7,置于含有抗生素(100U/mL青霉素、100μg/mL链霉素)和10%胎牛血清(FBS)的DMEM完全培养基中,在37℃、5%CO2的孵箱中培养。
实验例1:对RAW264.7细胞增殖作用
选取对数生长期的RAW264.7细胞,以3×105/mL的密度、每孔100μL接种于96孔板,至37℃、5%CO2的培养箱中培养24h,除去上清液,空白组加入DEME溶液1mL,模型组和实验组加入含有LPS(1μg/mL)的DEME溶液1mL,实验组加入含有不同浓度(3.125、6.25、12.5、25、50μmol/L)的本发明式Ⅰ化合物的DEME溶液,阳性对照组加入100ug/ml的***,于37℃、5%CO2培养箱中分别培养24h。弃去96孔板中原有培养液,在避光条件下加入100μL无血清培养液以及10μL CCK-8溶液,设置无细胞的复孔为空白组。将细胞孔板置于细胞培养箱中避光孵育3h,酶标仪于450nm处平行测定3次吸光度(A450)值,计算细胞相对存活率。如图2,研究发现本发明式Ⅰ化合物对在一定摩尔浓度范围内(25~50μmol/L)可以明显抑制RAW264.7巨噬细胞增殖(P<0.05),且具有浓度依赖性,对RAW264.7细胞增殖有明显抑制作用。
实验例2:Elisa法检测RAW264.7细胞炎性因子TNF-α释放量
选取对数生长期的RAW264.7细胞,以3×105/mL的密度、每孔100μL接种于96孔板,至37℃、5%CO2的培养箱中培养24h,除去上清液,空白组加入DEME溶液1mL,模型组和实验组加入含有LPS(1μg/mL)的DEME溶液1mL,0.5h后实验组分别加入含有化合物(25μmol/L)的DEME溶液1mL,于37℃、5%CO2孵箱中培养24h,以Elisa试剂盒检测炎性因子TNF-α水平,并根据标准曲线计算其含量。由图3可知与空白组比较,LPS可以升高RAW264.7巨噬细胞TNF-α释放量,具有显著性差异(P<0.05)。加入本发明式Ⅰ化合物(25μmol/L)进行处理后,可以有效降低RAW264.7细胞分泌TNF-α炎性因子能力,表明本发明式Ⅰ化合物通过降低TNF-α释放量表现出抗炎活性。
实验例3:Griess法测定NO释放量
选取对数生长期的RAW264.7细胞,以3×105/mL的密度、每孔100μL接种于96孔板,至37℃、5%CO2的培养箱中培养,按照试剂盒说明书制备NO标准曲线。空白组加入DEME溶液1mL,模型组和实验组加入含有LPS(1μg/mL)的DEME溶液1mL,0.5h后实验组分别加入含有本发明式Ⅰ化合物(6.25、12.5μmol/L)的DEME溶液1mL,24h后,离心(1 000g,15min),吸取50μL培养上清于96孔细胞培养板,各孔加入50μL Griess试剂A并混合,室温避光静置5min,各孔再加入50μL Griess试剂B并混合,室温避光静置10min,酶标仪540nm检测吸光度(A540),并用校准曲线确定实验各组NO的浓度,每个组重复6个孔。评价对一氧化氮(NO)的抑制作用。其NO抑制率按如下公式计算:NO抑制率=(A造模组-A药物组)/(A造模组-A空白组)×100%。
如图4所示,LPS可以增加巨噬细胞上清液中NO释放量,具有显著性差异(P<0.05)。加入本发明式Ⅰ化合物(6.25、12.5μmol/L)进行处理后,经本发明式Ⅰ化合物(6.25、12.5μmol/L)处理的RAW264.7巨噬细胞上清液中NO含量明显降低(P<0.05),且具有浓度依赖性,表明本发明式Ⅰ化合物可以通过降低NO释放量表现出抗炎活性。
以LPS作为诱导剂,刺激RAW264.7巨噬细胞建立炎症模型,对分离得到的本发明式Ⅰ化合物进行体外抗炎活性评价研究。首先采用CCK-8法检测不同浓度下本发明式Ⅰ化合物的细胞毒性,发现本发明式Ⅰ化合物在一定浓度范围内(25~50μmol/L)可抑制炎症细胞增殖且成浓度依赖性。然后通过Elisa法检测TNF-α炎症因子释放量,发现25μmol/L的本发明式Ⅰ化合物相较于模型组均可以降低TNF-α的释放量;Griess法检测NO释放量,发现6.25、12.5μmol/L的本发明式Ⅰ化合物相较于模型组均可以降低RAW264.7巨噬细胞NO释放量,实验结果表明本发明式Ⅰ化合物的抗炎作用主要与抑制炎症因子TNF-α和NO释放量有关。
综上,本发明化合物,结构如式Ⅰ,化学式为C23H18O8,化学命名为化学命名为1″-甲氧基-3,5,7,4',3″′,4″′-六羟基黄酮,并命名为芙蓉花素,英文名Mutabilfloin。首次由木芙蓉花提取物中提取分离纯化而得,具有明确的抗炎作用。
Claims (10)
1.化合物,其特征在于:结构如式Ⅰ,化学式为C23H18O8:
2.权利要求1所述的化合物的制备方法,其特征在于:包括如下步骤:
A、粉碎干燥木芙蓉花,用乙醇提取,收集滤液,除去乙醇,得到木芙蓉花乙醇提取物粗浸膏;
B、步骤A所得木芙蓉花乙醇提取物粗浸膏加水混悬,分别使用60~90℃的石油醚、乙酸乙酯、水饱和正丁醇依次萃取3-5次,分别收集萃取液,除去萃取液,分别得到石油醚部位、乙酸乙酯部位、正丁醇部位,剩余为水相部位;
C、取乙酸乙酯部位经正相硅胶柱色谱分离,以石油醚-乙酸乙酯为洗脱***进行梯度洗脱,收集馏分用TLC进行检视合并,依次得到7个组分,命名为Fr.YA~Fr.YG,收集Fr.YC备用;
D、取步骤C所得Fr.YC用MCI中压柱进行分离,以甲醇-水溶剂***进行梯度洗脱,收集馏分用TLC进行检测合并,依次得到以下组分,分别命名为Fr.YC1~13,收集Fr.YC 6备用;
E、取步骤D所得Fr.YC 6,经半制备液相纯化,以体积分数62%甲醇溶液为流动相,得到式Ⅰ化合物。
3.根据权利要求2所述的化合物的制备方法,其特征在于:至少满足以下任意一项:
所述干燥木芙蓉花,即开花期采摘初开放的花朵或待开放的花蕾,晒干或烘干即得;
步骤A所述乙醇为体积分数70-100%乙醇;
优选的,步骤A所述乙醇为体积分数90%乙醇;
步骤A所述提取方法为回流提取;
步骤A所述提取方法中回流提取的提取条件为1-3次,每次0.5-3小时;
优选的,步骤A所述提取方法中回流提取的提取条件为提取条件为2次,每次2小时;
步骤A所述除去乙醇的方法采用减压回收,以无醇味为终点;
步骤B中木芙蓉花乙醇提取物粗浸膏加水量为8-12倍量;
优选的,步骤B中木芙蓉花乙醇提取物粗浸膏加水量为10倍量;
步骤B中所述水为超纯水;
步骤B依次采用等体积的60~90℃的石油醚、乙酸乙酯、水饱和正丁醇萃取;
步骤B依次采用60~90℃的石油醚、乙酸乙酯、水饱和正丁醇萃取的次数为1-5次;
优选的,步骤B依次采用60~90℃的石油醚、乙酸乙酯、水饱和正丁醇萃取的次数为3次;
步骤C石油醚-乙酸乙酯溶剂***为按照20:1,8:1,5:1,2:1,1:1,1:2,1:4,1:10,0:100梯度进行洗脱,收集;
步骤C所得Fr.YC对应为石油醚:乙酸乙酯=2:1洗脱的部分;
步骤D甲醇-水溶剂洗脱***依次为50:50,60:40,70:30,80:20,90:10,100:0,收集馏分用TLC进行检测合并,依次得到以下组分,分别命名为Fr.YC1~13;
步骤D所得Fr.YC 6对应为甲醇-水溶剂***=60:40洗脱的部分,即60%甲醇。
4.根据权利要求2所述的化合物的制备方法,其特征在于:至少满足以下任意一项:
步骤C中,取乙酸乙酯部位80g,经正相硅胶柱色谱分离,以石油醚-乙酸乙酯为洗脱***按照20:1,8:1,5:1,2:1,1:1,1:2,1:4,1:10,0:100进行梯度洗脱,收集,共接馏分127瓶;然后收集的127瓶馏分经TLC进行检视合并,得到7个组分,命名为Fr.YA~Fr.YG,其中,1-15为Fr.YA,26-37为Fr.YB,38-52为Fr.YC,53-68为Fr.YD,69-90为Fr.YE,91-109为Fr.YF,110-127为Fr.YG;收集Fr.YC备用,所得Fr.YC对应为石油醚:乙酸乙酯=2:1洗脱的部分;
步骤D中,按步骤C取乙酸乙酯部位80g计算,甲醇-水溶剂洗脱***依次为50:50,60:40,70:30,80:20,90:10,100:0,共接馏分90瓶;用TLC进行检测合并,依次得到以下组分,分别命名为Fr.YC1~13,其中:1-4为Fr.YC 1,5-9为Fr.YC 2,10-13为Fr.YC 3,14-19为Fr.YC4,20-24为Fr.YC 5,25-28为Fr.YC 6,29-33为Fr.YC 7,34-38为Fr.YC 8,39-44为Fr.YC 9,45-48为Fr.YC 10,49-62为Fr.YC 11,63-79为Fr.YC 12,80-90为Fr.YC 13;所得Fr.YC 6对应为甲醇-水溶剂***=60:40洗脱的部分,即60%甲醇;
步骤E经半制备液相纯化,以体积分数62%甲醇溶液为流动相,出峰时间33min。
5.根据权利要求2所述的化合物的制备方法,其特征在于:包括如下步骤:
A、将干燥木芙蓉花粉碎成粗粉,用体积分数90%乙醇回流提取2次,每次2h,滤过后合并滤液,减压回收至无醇味,得到木芙蓉花乙醇提取物粗浸膏;
B、加入10倍量超纯水混悬提取物,分别使用等体积60~90℃石油醚、乙酸乙酯、水饱和正丁醇依次萃取3次,合并各萃取液,减压回收,得到石油醚部分、乙酸乙酯部分、正丁醇部分,剩余为水相部位;
C、取乙酸乙酯部位经正相硅胶柱色谱分离,以石油醚-乙酸乙酯=20:1,8:1,5:1,2:1,1:1,1:2,1:4,1:10,0:100为洗脱***进行梯度洗脱,收集馏分,共接馏分127瓶,用TLC进行检视合并,依次得到7个组分,命名为Fr.YA~Fr.YG,其中,1-15为Fr.YA,26-37为Fr.YB,38-52为Fr.YC,53-68为Fr.YD,69-90为Fr.YE,91-109为Fr.YF,110-127为Fr.YG,收集Fr.YC备用;D、取步骤C所得Fr.YC用MCI中压柱进行分离,以甲醇-水=50:50,60:40,70:30,80:20,90:10,100:0为溶剂***进行梯度洗脱,收集馏分,共接馏分90瓶,用TLC进行检测合并,依次得到以下组分,分别命名为Fr.YC1~13,其中:1-4为Fr.YC 1,5-9为Fr.YC 2,10-13为Fr.YC 3,14-19为Fr.YC 4,20-24为Fr.YC 5,25-28为Fr.YC 6,29-33为Fr.YC 7,34-38为Fr.YC 8,39-44为Fr.YC 9,45-48为Fr.YC 10,49-62为Fr.YC 11,63-79为Fr.YC 12,80-90为Fr.YC 13,收集Fr.YC 6备用;
E、取步骤D所得Fr.YC 6,经半制备液相纯化,以体积分数62%甲醇溶液为流动相,出峰时间33min,得到式Ⅰ化合物。
6.权利要求1所述化合物具有在制备抗炎的药物、保健品、化妆品、兽药中的用途。
7.权利要求1所述的化合物制备的药物,其特征在于:以所述式Ⅰ化合为原料,加入药学上可接受的辅助性成分制备而得的药物。
8.权利要求1所述的化合物制备的保健品,其特征在于:以所述式Ⅰ化合为原料,加入保健品可接受的辅助性成分制备而得的保健品。
9.权利要求1所述的化合物制备的化妆品,其特征在于:以所述式Ⅰ化合为原料,加入化妆品可接受的辅助性成分制备而得的化妆品。
10.权利要求1所述的化合物制备的化妆品,其特征在于:以所述式Ⅰ化合为原料,加入兽药可接受的辅助性成分制备而得的兽药。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210467131.5A CN117003720A (zh) | 2022-04-29 | 2022-04-29 | 化合物芙蓉花素及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210467131.5A CN117003720A (zh) | 2022-04-29 | 2022-04-29 | 化合物芙蓉花素及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117003720A true CN117003720A (zh) | 2023-11-07 |
Family
ID=88571463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210467131.5A Pending CN117003720A (zh) | 2022-04-29 | 2022-04-29 | 化合物芙蓉花素及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117003720A (zh) |
-
2022
- 2022-04-29 CN CN202210467131.5A patent/CN117003720A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004052383A1 (fr) | Composition contenant des saponines triterpenoides extraites de bambou, son procede de preparation et son utilisation | |
CN103242398B (zh) | 二氢黄酮化合物及其制备方法与应用 | |
CN112159378B (zh) | 一种吉马烷型倍半萜内酯类化合物及其制备方法和应用 | |
CN105943532A (zh) | 一种二萜类化合物在制备治疗肝癌的药物中的应用 | |
CN113754533A (zh) | 氧化半日花烷型二萜类化合物及其分离方法和应用 | |
CN106008543A (zh) | 一种新的二萜类化合物及其制备方法 | |
CN111018877B (zh) | 一种土木香中倍半萜类衍生物、其制备方法及应用 | |
CN101190259A (zh) | 一种广玉兰总内酯提取物及其制备方法和应用 | |
CN117003720A (zh) | 化合物芙蓉花素及其制备方法和用途 | |
CN112898357B (zh) | 金莲花中一种二萜苷类新化合物及其分离纯化方法和应用 | |
CN105646638B (zh) | 长梗冬青苷的制备方法 | |
CN102048714A (zh) | 苯二酚类化合物在制备抗补体药物中的用途 | |
CN108948040B (zh) | 一种烟管头草中提取的吉玛烷型倍半萜化合物及其应用 | |
CN111377933B (zh) | 诸葛菜种子提取的生物碱类化合物及其提取方法与应用 | |
CN117003804A (zh) | 吲哚类化合物及其制备方法和用途 | |
CN112250655A (zh) | 两种新的环状二苯基庚烷类化合物及其制备方法和用途 | |
CN109206392B (zh) | 一种香豆素类化合物及其制备方法与应用 | |
CN107082780B (zh) | 一种具有吡咯骈异喹啉结构的生物碱及其制备方法与应用 | |
CN112979728B (zh) | 一种聚合裂环环烯醚萜苷类化合物及其制备方法和应用 | |
CN116693480B (zh) | 二氢白蜡酮a及其制备方法和应用 | |
CN111329866A (zh) | 一种五环三萜类化合物在制备抗偏头痛药物中的应用 | |
CN116693485B (zh) | 白鲜酯c及其制备方法和应用 | |
CN103665090B (zh) | 枸骨皂苷化合物、其制备方法及应用 | |
CN105777839B (zh) | 一种抗肿瘤化合物、其提取方法及其应用 | |
CN109810153A (zh) | 芳香取代葡萄糖类化合物及其药物组合物的制备方法与镇痛应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |